本文關鍵詞： 糖尿病腎病 顆粒蛋白前體 足細胞 自噬　出處：《山東大學》2017年碩士論文　論文類型：學位論文

【摘要】：研究背景:糖尿病腎病(diabetic nephropathy,DN)是導致終末期腎病(end stage renal disease,ESRD)的最重要的誘因之一,嚴重威脅人類的生命健康。糖尿病腎病的發(fā)病機制尤為復雜,主要包括糖脂代謝紊亂、血流動力學、氧化應激、炎癥反應以及遺傳因素等。足細胞(podocyte)是維持腎小球內環(huán)境穩(wěn)態(tài)的重要組成部分,足細胞與腎小球內皮細胞和基底膜共同組成了腎小球濾過屏障,足細胞損傷是糖尿病腎病的早期事件,可導致濾過屏障遭到破壞,產(chǎn)生蛋白尿,最終加重腎臟損傷。但是,在糖尿病腎病中造成足細胞損傷的機制尚不完全明確。顆粒蛋白前體(progranulin,PGRN)是一種自分泌型生長因子,廣泛表達分布于體內各種組織與器官,例如神經(jīng)細胞、軟骨細胞、免疫細胞以及上皮細胞等。PGRN具有諸多生物學功能,廣泛參與到多種病理生理過程中,如腫瘤的發(fā)生發(fā)展、自身免疫類疾病、組織損傷修復、傷口愈合等。雖然課題組前期的研究證明PGRN可以通過負調控NOD2介導的信號通路在急性腎損傷中起到保護作用,但在糖尿病腎病中是否發(fā)揮作用尚不清楚。研究表明,自噬在糖尿病腎病的病理進程中發(fā)揮著重要的作用,正常生理條件下足細胞保持著較高的自噬水平,糖尿病腎病發(fā)生時足細胞自噬水平降低導致足細胞受損進而加重腎損傷。報道顯示,AMPK是自噬的激活劑,AMPK可以通過直接磷酸化自噬啟動蛋白ULK1從而促進自噬,進而在糖尿病腎病中起到保護作用。因此本實驗主要為了探究PGRN在糖尿病腎病中的作用,以及是否與自噬,AMPK信號通路有關。研究方法與結果1.PGRN在糖尿病腎病中的表達變化選取8-12周齡雄性野生型(wild type,WT)C57BL/6J小鼠,單腎摘除后恢復一周,腹腔注射鏈脲佐霉素(streptozotocin,STZ)100mg/kg連續(xù)三天誘導糖尿病腎病。當小鼠模型構建成功后,使用蛋白免疫印跡法(Western blot,WB)、Real-time RT-PCR、免疫熒光(immunofluorescence,IF)和免疫組化(immunohistochemistry,IHC),檢測PGRN在腎皮質中表達變化及分布情況,結果顯示PGRN在糖尿病腎病模型組腎皮質中與對照組相比表達明顯下降。同時體外高糖分別刺激人腎小球足細胞(humanpodocyte,HPC)、內皮細胞(glomerular endothelial cell,GEnC)和大鼠系膜細胞(rat messangial cell,RMC)結果顯示,腎小球足細胞和內皮細胞中的PGRN均表達下降。2.PGRN在糖尿病腎病損傷中的作用適齡野生型雄性C57BL/6小鼠和Grn基因敲除鼠(B6(Cg)-Grntml lAidi/J)隨機分組,分別構建糖尿病腎病模型和對照組。通過PAS對野生型和Grn基因敲除組腎臟石蠟切片染色,透射電鏡觀察小鼠足細胞損傷。結果顯示,在糖尿病腎病組PGRN的缺失導致了腎皮質中腎小球系膜基質增生加重。透射電鏡結果顯示PGRN的缺失加重了腎小球足細胞損傷,導致足細胞足突的融合消失。IF標記足細胞特異性蛋白Nephrin、Podocin結果顯示PGRN的缺失加重了足細胞功能蛋白的損傷。同時Real-time RT-PCR檢測野生型與Grn基因敲除鼠腎皮質炎性因子與趨化因子的變化,結果顯示,PGRN的缺失導致腎皮質中炎性因子與趨化因子較野生型糖尿病腎病組更高。體外流式細胞術檢測足細胞凋亡水平,結果顯示加入重組PGRN可以明顯降低高糖引起的細胞凋亡,WB檢測足細胞功能蛋白Nephrin,結果顯示加入重組PGRN可恢復高糖誘導的Nephrin蛋白水平的降低。3.PGRN在糖尿病腎病損傷中的作用機制WB檢測野生型與Grn基因敲除鼠腎皮質中LC3B等自噬相關分子,結果顯示Grn基因敲除鼠糖尿病腎病組較野生型糖尿病腎病組的自噬水平更低。體外結果顯示足細胞高糖條件下自噬水平顯著降低,加入重組PGRN后自噬水平恢復,Tandem實驗觀察自噬流變化表明加入重組PGRN可以恢復足細胞高糖條件下自噬流水平。同時WB檢測自噬啟動蛋白ULK1磷酸化水平,結果表明高糖條件下ULK1磷酸化水平降低,加入重組PGRN可以恢復磷酸化水平。進一步WB檢測糖尿病腎病腎皮質AMPK信號通路的水平,結果顯示糖尿病腎病組中Grn基因敲除較野生型AMPK信號通路進一步降低。結論與創(chuàng)新性:1.糖尿病腎病小鼠模型中PGRN顯著降低,PGRN的缺失加重糖尿病腎病足細胞損傷。2.PGRN可以通過激活AMPK信號通路促進ULK1磷酸化水平進而啟動足細胞自噬。本課題對指導設計PGRN作為靶點治療糖尿病腎病提供重要的依據(jù)。
[Abstract]:Background: diabetic nephropathy (diabetic, nephropathy, DN) is the leading cause of end-stage renal disease (end stage renal disease, ESRD) is the most important factor, a serious threat to human life and health. The pathogenesis of diabetic nephropathy is very complex, mainly including glucose and lipid metabolism disorders, hemodynamics, oxidative stress, inflammatory reaction and genetic factors podocyte. (podocyte) is an important part of maintaining homeostasis within the glomeruli, glomerular podocytes and endothelial cells and basement membrane composed of glomerular filtration barrier, podocyte injury is an early event of diabetic nephropathy, can lead to the destruction of the filtration barrier, resulting in proteinuria, eventually aggravate renal injury. But the mechanism caused by foot cell damage is still not completely clear in diabetic nephropathy. Progranulin (progranulin, PGRN) is an autocrine growth factor expression, widely divided The cloth in various tissues in the body and organs, such as nerve cells, cartilage cells, immune cells and epithelial cells,.PGRN has many biological functions, widely involved in the pathological process of many kinds, such as the occurrence and development of tumors, autoimmune diseases, tissue repair and wound healing. Although our previous studies have demonstrated that PGRN can signaling through negative regulation mediated by NOD2 in acute kidney injury plays a protective role in diabetic nephropathy, but the role is not clear. Studies suggest that autophagy plays an important role in the pathological process of diabetic nephropathy, normal physiological conditions of podocyte autophagy maintained higher levels of diabetic nephropathy. Occurs when the podocyte autophagy leading to podocyte damage and reduce the level of renal damage aggravated. Reports indicate that AMPK is the activator of autophagy, AMPK through direct phosphorylation of autophagy Start the ULK1 protein to promote autophagy, which play a protective role in diabetic nephropathy. So this experiment in order to explore the role of PGRN in diabetic nephropathy, and whether autophagy, AMPK signaling pathway. The research methods and results of 1.PGRN in diabetic nephropathy on the expression of selected 8-12 week old male wild type (wild type WT, C57BL/6J) mice, single kidney removed recovery after a week, intraperitoneal injection with streptozotocin (streptozotocin, STZ) 100mg/kg for three days induced diabetic nephropathy. When the successful construction of mouse model, using Western blotting (Western blot, WB), Real-time RT-PCR, immunofluorescence (immunofluorescence, IF) and immunohistochemistry (immunohistochemistry, IHC), the expression and distribution of PGRN was detected in renal cortex, showed that PGRN in the cortex of kidney in diabetic nephropathy model group compared with the control group was significantly decreased. At the same time were stimulated with high glucose in vitro human glomerular podocyte (humanpodocyte, HPC), endothelial cells (glomerular endothelial cell, GEnC) and rat mesangial cells (rat messangial cell, RMC) results showed that glomerular podocytes and endothelial cells in the expression of PGRN was decreased in diabetic nephropathy.2.PGRN injury age of wild type male C57BL/6 mice and Grn knockout mice (B6 (Cg) -Grntml lAidi/J) were randomly divided into diabetic nephropathy model were constructed and the control group. The PAS knockout group staining on paraffin sections of kidney and wild type Grn gene, observe the podocyte injury in mice by transmission electron microscope. The results showed that in the absence of PGRN in diabetic nephropathy group glomerular mesangial matrix hyperplasia in renal cortex increased. TEM results showed that deletion of PGRN increased glomerular podocyte injury, leading to podocyte footprocess fusion disappear podocyte.IF markers Specific protein Nephrin, Podocin results showed that PGRN deletion aggravated the injury of podocyte proteins. At the same time, Real-time RT-PCR detection of wild-type and Grn knockout rat renal cortex changes, inflammatory cytokines and chemokines showed that deletion of PGRN leads to inflammatory factors in renal cortex and chemotactic factor than the wild type diabetic nephropathy was higher in vitro. Flow cytometry was used to detect the apoptosis of podocyte levels, the results showed that the addition of recombinant PGRN can significantly reduce the cell apoptosis induced by high glucose, WB detection of podocyte protein Nephrin, the results showed that Nephrin protein levels with recombinant PGRN can restore glucose induced WB reduction mechanism of.3.PGRN in injury in diabetic nephropathy detection of wild-type and Grn knockout LC3B rats renal cortex autophagy related molecules, the results showed that Grn knockout mice diabetic nephropathy group compared with the wild type diabetic nephropathy The in vitro results showed lower levels of autophagy. Podocyte autophagy under high glucose decreased significantly and the recovery of autophagy with recombinant PGRN, Tandem experimental observation indicated that the addition of recombinant PGRN autophagy flow can restore podocytes under high glucose levels. At the same time WB for the detection of autophagy flow autophagy protein ULK1 phosphorylation level. The results show that the phosphorylation of ULK1 under the condition of high glucose levels decreased with recombinant PGRN can restore the phosphorylation level of WB. Further detection of diabetic nephropathy renal cortical AMPK signaling level, results showed that the diabetic nephropathy group compared to the wild type Grn gene knockout AMPK signal pathway is further reduced. The conclusion and Innovation: PGRN 1. diabetic nephropathy mice decreased significantly, PGRN the lack of increase of podocyte injury in diabetic nephropathy.2.PGRN can activate the AMPK signaling pathway to promote ULK1 phosphorylation and initiation of podocyte Autophagy. This topic provides an important basis for guiding the design of PGRN as a target for the treatment of diabetic nephropathy.

【學位授予單位】：山東大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R587.2;R692.9

【相似文獻】

相關期刊論文 前10條

1 王靜,阮蕓,徐冬娥,譚擎纓;多項指標聯(lián)檢對診斷早期糖尿病腎病的意義[J];浙江臨床醫(yī)學;2000年04期

2 王玉新,李大啟,李公寶,徐琴君;糖尿病腎病患者血清可溶性白細胞介素6受體檢測[J];上海免疫學雜志;2001年02期

3 宮雅南,劉冬年,熊玉冰,黃偉文,莊萬江;糖尿病足患者糖尿病視網(wǎng)膜病變分析[J];廣東醫(yī)學;2001年06期

4 顧芹,宋守君,李向陽,尤傳一;胰激肽原酶腸溶片對早期糖尿病腎病的防治作用[J];中國臨床藥學雜志;2001年06期

5 曹愛華 ,王瑛 ,李翔;杏丁治療早期糖尿病腎病療效觀察[J];遼寧實用糖尿病雜志;2001年03期

6 ;中藥治療糖尿病腎病新進展[J];中國中醫(yī)藥信息雜志;2001年04期

7 張桂茹;糖尿病腎病85例臨床分析[J];陜西醫(yī)學雜志;2002年02期

8 侯建明 ,林鳳輝 ,張超群;46例2型糖尿病腎病與糖尿病自主神經(jīng)病變的關系分析[J];福建醫(yī)藥雜志;2002年04期

9 陳文霖;糖尿病飲食[J];醫(yī)療保健器具;2002年Z1期

10 孫力,許玲;2型糖尿病患者糖尿病足的危險因素分析[J];山東醫(yī)藥;2002年35期

相關會議論文 前10條

1 張星;許筠;蘇建平;張軍;程立志;翟曉麗;;糖尿病腎病的臨床療效對比觀察[A];第十九次全國中醫(yī)腎病學術交流會論文匯編[C];2006年

2 楊家茂;;糖尿病腎病防治瑣談[A];全國第二屆中醫(yī)中西醫(yī)結合腎臟病臨床進展學術研討會論文集[C];2007年

3 丁耀耿;郝桂霞;;糖尿病腎病臨床分析[A];全國第二屆中醫(yī)中西醫(yī)結合腎臟病臨床進展學術研討會論文集[C];2007年

4 張文鎧;王志伏;王雪;孫大朋;;糖尿病腎病的治療現(xiàn)狀[A];中華中醫(yī)藥學會第二十一屆全國中醫(yī)腎病學術會議論文匯編（下）[C];2008年

5 倪青;;糖尿病腎病的中西醫(yī)結合研究[A];第六屆全國中西醫(yī)結合腎臟病學術會議論文匯編[C];2000年

6 孫怡;李健紅;宗紅燕;;黃芪桂枝五物湯加味治療糖尿病腎病16例[A];第六屆全國中西醫(yī)結合腎臟病學術會議論文匯編[C];2000年

7 葉軍;;糖尿病腎病在兒童時期的早期干預[A];中華醫(yī)學會第六次全國內分泌學術會議論文匯編[C];2001年

8 杜旭昶;孫志紅;閆春芳;劉彩虹;;疏糖丹治療2型糖尿病50例臨床分析[A];第六次中國中西醫(yī)結合糖尿病學術會議論文匯編[C];2002年

9 于世家;任平;馬麗佳;李小娟;鄭曙琴;武明東;劉自力;薛麗輝;;糖尿病住院患者1344例回顧性分析[A];第六次中國中西醫(yī)結合糖尿病學術會議論文匯編[C];2002年

10 郝效槐;魏玫都;崔立俊;;中西并蓄治療糖尿病腎病[A];第七次中國中西醫(yī)結合糖尿病學術會議論文匯編[C];2004年

相關重要報紙文章 前10條

1 本報記者 向佳;糖尿病中醫(yī)藥防治項目立足社區(qū)[N];中國中醫(yī)藥報;2011年

2 特約記者 魯海燕;逾八成公眾存在糖尿病高危因素[N];家庭醫(yī)生報;2013年

3 馬明愈;現(xiàn)代生活方式導致 糖尿病發(fā)病率迅速上升[N];中國婦女報;2005年

4 省立醫(yī)院內分泌科主任醫(yī)師 侯建明;糖尿病腎病的防治[N];福建科技報;2004年

5 王文絹 范軍星;世界糖尿病日關注焦點:糖尿病并發(fā)癥[N];健康報;2003年

6 主持人 向紅丁博士;糖尿病腎病須早防早治[N];人民政協(xié)報;2002年

7 華悅;預防糖尿病，從減肥開始[N];上海中醫(yī)藥報;2004年

8 劉冬梅;肥胖糖尿病第一誘因[N];天津日報;2004年

9 劉燕玲;首部中醫(yī)專病指南定下糖尿病治則[N];健康報;2007年

10 崔昕;中藥防治糖尿病腎病有進展[N];健康時報;2006年

相關博士學位論文 前10條

1 王曉杰;組蛋白去乙酰化酶4特異性促進糖尿病腎病足細胞損傷[D];山東大學;2015年

2 張永;MiR-346在抗TGF-β信號途徑介導的糖尿病腎病發(fā)生和發(fā)展中的作用機制[D];武漢大學;2015年

3 魏鳳江;高尿酸血癥、2型糖尿病及糖尿病微血管病變的群體遺傳學研究[D];天津醫(yī)科大學;2015年

4 孫士杰;胱抑素C對2型糖尿病視網(wǎng)膜病變預測價值研究[D];山東大學;2015年

5 龍泓竹;益氣養(yǎng)陰通絡散結方防治早期糖尿病腎病的臨床及實驗研究[D];北京中醫(yī)藥大學;2016年

6 姜e，

本文編號：1492275